尊龙凯时·「中国区」官方网站

2021-06-01 GP (HK) Appoints Mr. Zhou Chao as CEO

2021-05-30 GP (HK) Exclusively Introduces Global Innovative Breakthrough Medical Device The New Generation Heartlight X3 Laser Ablation Platform from Cardiofocus

2021-05-26 GP (HK) Acquires Shenming Medical Technology Co., Ltd. Obtains All Rights of an Innovative Thermosensitive Embolic Agent for the Treatment of Liver Cancer. Further Expands the Tumor Intervention Treatment Product Pipeline

2021-05-24 GP (HK)’s Global Innovation Product STC3141 Enrolled and Dosed Four Patients for the Phase IIa Clinical Trial of Covid-19 in Belgium Rapidly Advance the Global Development Process

2021-05-09 GP (HK)’s Blockbuster Product SIR-Spheres® Y-90 Resin Microspheres Completes the First Patient Administration

2021-04-20 GP (HK)’s Global Innovation Product STC3141 Receives Approval for a Phase IIa Clinical Trial of COVID-19 in Belgium

2021-03-19 GP (HK) Announces 2020 Annual Results Profit

2021-03-09 SIR-Spheres® Y-90 Resin Microspheres Obtains Recommendation from NICE and Approval from the FDA

2021-03-04 GP (HK)’s Independently Developed Innovative Glaucoma Treatment Drug Obtained Drug Registration Certificate

2021-03-04 GP (HK)’s First-In-Class Drug STC3141 for Sepsis has been Granted A “Notice of Approval for Clinical Trial of Drugs” Issued by the NMPA

2021-02-21 GP (HK) Announces Positive Profit Alert

2020-12-13 First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141 Promote Commercialization